|Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
in situ hybridization and immunohistochemistry showed that TGFBR-II conditional deficient mice had growth and differentiation abnormality of growth plate chondrocytes in endoplates. This abnormality was not improved by IGF-I injection. Next, to discover new drugs for the treatment of vertebral disc degeneration, we screened about 2000 chemical reagents using TGFBR-II null primary chondrocytes, and so far we have not got a targetreagent yet.